Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib + Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia
NCT04263480Phase 2Active, not recruiting
- Start
- Aug 2021
- Primary completion
- May 2028
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of carfilzomib in Waldenström's macroglobulinemia (WM). Started Aug 2021; status: active, not recruiting.
02
Drugs
carfilzomib
03
Conditions
Waldenström's macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04263480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263480.